Biopharma Cred. Regulatory News (BPCR)

BioPharma Credit plc

(the "Company")

TRANSACTION IN OWN SHARES

BioPharma Credit PLC (the "Company") announces that today it has purchased the following number of its ordinary shares of US$0.01 each on the London Stock Exchange through J.P. Morgan Securities plc into treasury.

Ordinary Shares: BPCR LN

Date of purchase: 26 February 2024

Number of ordinary shares purchased: 1,399,346

Lowest price per share: $0.8860

Highest price per share: $0.8900

Trading venue: London Stock Exchange

Ordinary Shares: BPCR LN

Date of purchase: 26 February 2024

Number of ordinary shares purchased: 250,000

Lowest price per share: $0.8900

Highest price per share: $0.8900

Trading venue: JPSI

Aggregate volume per date per trading venue: 1,649,346

Weighted average price per day per trading venue: $0.8897

Following the above transaction, the Company holds 120,294,222 of its ordinary shares in treasury and has 1,253,637,845 ordinary shares in issue (excluding treasury shares). Therefore, the total number of voting rights in the Company is 1,253,637,845. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0) 333 300 1950

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24